Quesada-López, T, Mestres-Arenas, A, Domingo, P, Prieto, P, Mur, I, Pérez, JAH, Guimaraes, MP, Villarroya, J, Gutiérrez, MD, Mateo, MG, Domingo, JC, Planavila, A, Villarroya, F, Giralt, M, Cereijo, R. Reduced circulating levels of CXCL14 are associated with cardiovascular damage in people living with HIV. EUROPEAN JOURNAL OF PHARMACOLOGY. 2025; 1003DOI:10.1016/j.ejphar.2025.177996. PMID:40714072. IF:4.700(Q1/2D).

Delgado-Arija, M, Carmena, MDGC, Martínez-Selles, M, Guerra, JM, Valdivielso, S, González-Juanatey, JR, Rivas-Lasarte, M, Roselló-Lleti, E, Perez-Villacastin, J, Carrasquer, A, Matute-Blanco, L, Grande-Trillo, A, Crespo-Leiro, MG, Delgado, JF, Martinez-Dolz, L. Plasma metabolites in patients of the REDINSCOR III registry hospitalised for de novo heart failure with preserved ejection fraction: Prognostic implications of linoleamide and 2-trans,4-cisdecadienoylcarnitine levels. Clinical and Translational Medicine. 2025; 15(9)DOI:10.1002/ctm2.70398. PMID:40947803. IF:6.800(Q1/2D).

Alonso-Ojembarrena, A, Poindexter, B, Aleem, S, Healy, H, Aguar-Carrascosa, M, Moliner-Calderón, E, Serrano-Martin, MD, Arroyo, R, Vento, M. A phase 1b randomized, multicenter, dose determination trial of zelpultide alfa (recombinant human surfactant protein D) in preterm neonates at high risk of developing bronchopulmonary dysplasia. Frontiers in Pediatrics. 2025; 13DOI:10.3389/fped.2025.1639573. PMID:41018057. IF:2.000(Q2/4D).

Park, HS, del Campo, PD, Plana, MN, La Borda, JPY, Guerra-Rodriguez, M, Moreno, M, Cañete, JD. Efficacy of withdrawal or tapering of bDMARDs vs. standard regimen in axial spondyloarthritis patients: systematic review and meta-analysis informing the update of the Spanish Society of Rheumatology Guideline. Frontiers in Medicine. 2025; 12DOI:10.3389/fmed.2025.1621313. PMID:41001393. IF:3.000(Q1/2D).